Reply to thread

The sad part is that any line extensions that are planned for their psoriasis drug will likely not be accepted for review until this is minor speed bump is fixed.  That is sad for a company that values getting medicine to patients with unmet needs....and yet quality is probably celebrating that that they didnt have bigger issues from the regulatory inspection.